Patent · US Expired

Anti-apoptotic use of human glutaminyl-tRNA synthetase with two consecutive pro-apoptotic mediators

US6548060B1 · kind B1 · utility

86Cited by
1References
4Claims
0Family size

Inventor

Key dates

Filing dateNov 18, 1999
Grant dateApr 15, 2003
Priority date—
Expiry dateNov 18, 2019

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/53
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Aminoacyl-tRNA synthetases are the enzymes catalyzing ligation of their cognate amino acids and tRNAs. Human glutaminyl-tRNA synthetase (QRS) consists of the unique N-terminal extension (236 aa) and the C-terminal catalytic domain (539 aa). Here, we found that the N- and C-domains of QRS interacted with pro-apoptotic mediator, Daxx, and its downstream kinase, ASK1 (apoptosis signal-regulating kinase), respectively. The experimental results suggest that QRS may inhibit the ASK1 activity via two different ways. First, its C-terminal domain made direct inhibitory interaction with ASK1. Second, it inhibited the pro-apoptotic interaction between Daxx and ASK1. QRS also blocked the Daxx-ASK1 mediated apoptosis. Thus, QRS is not only an enzyme for protein synthesis but also plays a regulatory role in apoptosis

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.